Ask AI
ProCE Banner Activity

Expert Insight on Seminal New Clinical Trial Data Presented at the 2023 IGCS Conference Informing Treatment for Endometrial, Ovarian, and Cervical Cancers

Podcast

In this podcast episode, listen to Brian Slomovitz, MD, MS, FACOG, and Keiichi Fujiwara, MD, PhD, discuss their takeaways from seminal clinical trial data for gynecologic cancers presented at the 2023 IGCS annual meeting.

Released: December 04, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, Genmab and Seagen.

AstraZeneca

Genmab

GlaxoSmithKline

Merck Sharp & Dohme Corp.

Novocure

Seagen

Additional Disclosures

Primary Author

Keiichi Fujiwara, MD, PhD

Professor of Gynecologic Oncology
Saiama Medical University International Medical Center
Hidaka, Japan
Professor of OBGYN
International University of Health and Welfare
Narita, Japan

Keiichi Fujiwara, MD, PhD: consultant/advisor/speaker: Genmab, Sanofi, Seagen, Takeda.

Brian M. Slomovitz, MD, MS, FACOG

Deputy Director, Braman Comprehensive Cancer Center
Director, Gynecologic Oncology
Mount Sinai Medical Center
Professor, Obstetrics and Gynecology, Florida International University
Professor, Obstetrics and Gynecology, New York Medical College
Member, Board of Directors, GOG Foundation
Uterine Cancer Clinical Trial Lead, GOG Partners
Miami, Florida

Brian Slomovitz, MD, MS FACOG: consultant/advisor/speaker: AstraZeneca, Clovis, Eisai, Genmab, Gilead, GlaxoSmithKline, Merck, Novartis, Novocure, Regeneron, Seagen.